Author Correction: Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study - Filipa Lynce; Candace Mainor; Renee N. Donahue; Xue Geng; Greg Jones; Ilana Schlam; Hongkun Wang; Nicole J. Toney; Caroline Jochems; Jeffrey Schlom; Jay Zeck; Christopher Gallagher; et al. (Nature Communications, 2024)